Should Biomarkers Be Used in the Clinical Management of ES-SCLC?

Determining the Most Effective Chemotherapy Regimen in Patients With Advanced KRAS-Mutated NSCLC: the NVALT22 study

… combination of taxanes with an angiogenesis inhibitor in search for better outcomes for patients with advanced …

Gender Disparity in Lung Cancer

… for gender-sensitive approaches in healthcare policy, research, and clinical practice. … Gender Disparity in Lung …

ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC

… Spigel, MD, Chief Scientific Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, as he began his …

When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience

… Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab …

Keynote Address Explores the Future of Biomarkers in the ADC Era

… R. Hirsch outlined the current state of knowledge in ADC research, as well as what still needs to be learned. … Keynote …

New Registry Aims to Expand Knowledge of Lung Cancer Treatment During Pregnancy

… spearheading the effort at Dana Farber, says the need for research on cancer therapies for pregnant patients is urgent …

TIL Therapy Endures for Carefully Selected Patients: A Q&A with Dr. Benjamin C. Creelan

… Benjamin C. Creelan shares his passion for cell therapy research and insights into current data. … TIL Therapy Endures …

Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

… new pragmatic approach to trial design can streamline research and ultimately benefit patients. … Pragmatic Approach …

Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

… Researchers evaluating the clinical significance of …

Undruggable No More: KRAS Experts Review What is Known—and Unknown—About This Challenging Alteration

… to target this oncogenic driver. Get up to date as researchers from Roswell Park Comprehensive Cancer Center …

Asandeutertinib Goes Head-to-Head With Osimertinib in Phase II ESAONA Trial